Table 1.

Peroxiredoxin Gene Expression and Cancer Survival

Cancer type	PRDX1	PRDX2	PRDX3	PRDX4	PRDX5	PRDX6
Breast	p = 0.002	p = 0.018	p = 0.001	p = 9.4e-06	p = 0.039	p = 0.001
	HR = 1.4 (1.13–1.74)	HR = 1.31 (1.05–1.63)	HR = 0.71 (0.57–0.87)	HR = 1.85 (1.4–2.45)	HR = 1.4 (1.02–1.93)	HR = 1.46 (1.17–1.82)
Gastric	p = 5.2e-07	p = 9.4e-13	p = 2.5e-11	p = 5.3e-09	p = 0.012	p = 0.0033
	HR = 0.65 (0.55–0.77)	HR = 0.54 (0.46–0.64)	HR = 0.54 (0.44–0.64)	HR = 0.60 (0.51–0.72)	HR = 0.75 (0.6–0.94)	HR = 0.77 (0.64–0.92)
Lung	p = 6.3e-08	p = 0.0025	p = 0.014	N.S.	p = 2e-07	p = 2.8e-08
	HR = 1.41 (1.25–1.6)	HR = 1.22 (1.07–1.38)	HR = 0.85 (0.75–0.97)		HR = 0.64 (0.54–0.76)	HR = 0.7 (0.61–0.79)
Ovarian	N.S.	N.S.	p = 0.045	N.S.	N.S.	p = 0.019
			HR = 1.15 (1–1.31)			HR = 1.18 (1.03–1.35)

The association between peroxiredoxin mRNA level and the overall survival of patients with breast, gastric, lung, or ovarian cancer was analyzed on public data of Km plotter (kmplot.com). For all cancers, auto select best cut-off was chosen and samples were censored at threshold. Samples analyzed included all available data sets; no restrict analysis to subtypes was done. For breast cancer, 1402 samples were analyzed; for gastric cancer, 876 samples were analyzed; and for lung cancer and ovarian cancer, 882 samples were analyzed. PRDX1 probe 208680_at, PRDX2 probe 39729_at, PRDX3 probe 201619_at, PRDX4 probe 201923_at, PRDX5 probe 1560587_s_at, and PRDX6 probe 200845_s_at were used. HR >1: survival is shorter with high expression; HR <1: survival is longer with high expression.

HR, hazard ratio; N.S., not significant.